TIDMDMTR
RNS Number : 0152L
DeepMatter Group PLC
11 May 2022
11 May 2022
DeepMatter Group Plc
DeepMatter extends licensing and collaboration agreement with
Standigm
DeepMatter Group Plc (AIM: DMTR, "Deepmatter", "the Group"), the
digital chemistry data and software company , has signed a second
multi-year licensing and collaboration agreement with Standigm Inc
. ("Standigm"), a leading workflow artificial intelligence (AI)
drug discovery company, based in South Korea with an increasing
international footprint.
The second agreement is expected to generate revenues for
DeepMatter of GBP280,000. DeepMatter's first licensing agreement
with Standigm was announced on 1 March 2022.
Following the successful deployment of DeepMatter's unique data
and laboratory integration platform earlier this year, the
agreement includes licen s ing for DeepMatter's proprietary
chemical structure and reaction data and machine-learning
Retrosynthesis Software. DeepMatter and Standigm will collaborate
to develop further AI-driven drug discovery capabilities, drawing
upon the Group's deep digital chemistry expertise.
Jinhan Kim, co-founder and CEO of Standigm :
"As a front-runner in AI drug discovery industry, we have
constantly adopted new approaches and technologies without
hesitation, to make AI standard in the pharmaceutical industry. In
the same vein, we took an early lead in digitalisation of
chemistry, which will dramatically reduce the labour needed to make
new compounds and broaden accessible chemical space.
"We are delighted to be continuing our long-term relationship
with DeepMatter, uniquely strengthening Standigm's workflow
artificial intelligence (AI) drug discovery capability with their
digital chemistry platforms."
Mark Warne , CEO of DeepMatter, commented:
"This second agreement with Standigm this year demonstrates our
unique portfolio capabilities and also deepens the collaboration
between our two businesses."
Hanjo Kim, SVP of Global Strategy, Standigm commented:
" We believe that this systemic innovation in chemistry from
adopting DeepMatter's platforms will facilitate Standigm's drug
discovery research, by stimulating ideas for alternative or novel
synthetic routes that otherwise may not be considered .
DeepMatter's capabilities are now an essential component of this
offering."
For more information contact
DeepMatter Group Plc
Fraser Benson, Chief Financial Officer 0141 548 8156
Canaccord Genuity Limited (Nominated Adviser and Broker) 020
7523 8000
Bobbie Hilliam
Meare Consulting 07990 858548
Adrian Duffield
Standigm Inc.
Sang Ah Lee sangah.lee@standigm.com
About DeepMatter Group plc
DeepMatter 's SmartChemistry(TM) platform enables scientists
across a range of industries, including pharma, biotech,
agri-science, scientific publishers and contract research
organisations (CROs), to easily capture, access and exploit the
vast amounts of data created in chemical reactions.
DeepMatter integrates its proprietary chemistry data and
proprietary software to significantly improve productivity,
efficiency, discovery, safety and sustainability of chemical
reactions for its customers.
DeepMatter's SmartChemistry(TM) platform capitalises on the
combination of its cloud technology, low cost-sensors, connectivity
to laboratory hardware and high-performance computing trends such
as artificial intelligence (AI).
Visit: www.deepmatter.io and follow @deepmattergroup
Standigm is a workflow AI-driven drug discovery company
headquartered in Seoul, South Korea, with subsidiaries in
Cambridge, UK, and Cambridge, MA, USA. Standigm has proprietary AI
platforms encompassing novel target identification to lead
generation to generate commercially valuable drug pipelines.
Founded in 2015, Standigm has established an early-stage drug
discovery workflow AI to generate multiple First-in-Class compounds
within seven months. Pursuing full-stack, AI-driven industrializing
drug discovery, Standigm has achieved the automation of molecular
design workflow . The automation effort has expanded to the whole
drug discovery process based on Standigm AI platforms, including
Standigm ASK(TM) for novel target discovery and Standigm BEST(TM)
for novel compounds generation.
Standigm has prestigious investors, including SK Holdings, SK
Chemicals and Pavilion Capital.
Learn more at http://www.standigm.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTGPUAPAUPPGMU
(END) Dow Jones Newswires
May 11, 2022 02:01 ET (06:01 GMT)
Grafico Azioni Deepmatter (LSE:DMTR)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Deepmatter (LSE:DMTR)
Storico
Da Dic 2023 a Dic 2024
